Emyria Signs Real-World Data Agreement with Zelira
Filed with ASX · · 2 pages · English
• Emyria will monitor the safety and efficacy of Zenivol™ treatment in patients diagnosed with chronic insomnia to inform Zelira’s path to further development and product registration • Leverages Emyria’s clinical and data expertise to monitor the safety and efficacy of Zenivol™ treatment in patients diagnosed with chronic insomnia • Zenivol recently received TGA approval for prescription to patie
Earlier from Emyria
- Preliminary Final Report and Full Year Statutory Accounts
- Emerald Clinics Successfully Raises $2.2m in Placement
- Record Appointments International Expansion and Name Change
- Emerald Signs RWE Contract with Canopy Growth UK Company
- EMDs Digital Health Platform Expands with New Technology
Later from Emyria
- Webinar on Global Partnership with Sapphire Medical Clinics
- Emyria Enters Data Deal with ZLD to Support Autism Trial
- Emyria Partners with Thought Leaders in Psychedelic Therapy
- Emyria Launches Drug Development Program Based on RWE
- Emyria Sees Strong Interest in IBS Study
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria